The Analysis Study of Clinical Benefits and Risk of Oral Anticoagulant Therapy in Patient with Chronic Kidney Disease : A Comprehensive Systematic Review
Keywords:
Chronic kidney disease, oral anticoagulant, benefit, managementAbstract
Background: Arterial hypertension and diabetes mellitus are the primary causes of Chronic kidney disease CKD, while CKD is recognized as an independent risk factor for the onset of CVD. The aim of this study to show about clinical benefits and risk of oral anticoagulant therapy in patient with chronic kidney disease. Methods: By the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. This search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed, SagePub, and Sciencedirect were used to do this. Result: Eight publications were found to be directly related to our ongoing systematic examination after a rigorous three-level screening approach. Subsequently, a comprehensive analysis of the complete text was conducted, and additional scrutiny was given to these articles. Conclusion: Although there is a need for cardiorenal consensus regarding anticoagulation in CKD, adequate selection of the anticoagulant type and careful monitoring are some extremely useful indications for overcoming management challenges.
References
Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol [Internet]. 2019 Feb 7;14(2):278–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29802125
Alhousani M, Malik SU, Abu-Hashyeh A, Poznanski NJ, Al-Hasan S, Roth DF, et al. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis. Thromb Res [Internet]. 2021;198:103–14. Available from: https://doi.org/10.1016/j.thromres.2020.11.036
Parker K, Hartemink J, Saha A, Mitra R, Lewis P, Power A, et al. A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease. J Nephrol [Internet]. 2022;35(8):2015–33. Available from: https://doi.org/10.1007/s40620-022-01413-x
Gomez -Fernández P, Martín Santana A, Arjona Barrionuevo J de D. Oral anticoagulation in chronic kidney disease with atrial fibrillation. Nefrologia. 2021;41(2):137–53.
Elenjickal EJ, Travlos CK, Marques P, Mavrakanas TA. Anticoagulation in Patients with Chronic Kidney Disease. Am J Nephrol [Internet]. 2024;55(2):146–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/38035566
Stoica MC, Gáll Z, Gliga ML, Caldararu CD, Székely O. Oral anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease. Med. 2021;57(5):1–13.
Law JP, Pickup L, Townend JN, Ferro CJ. Anticoagulant strategies for the patient with chronic kidney disease. Clin Med J R Coll Physicians London. 2020;20(2):151–5.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England) [Internet]. 2020 Feb 29;395(10225):709–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32061315
Cho MS, Choi HO, Hwang KW, Kim J, Nam GB, Choi KJ. Clinical benefits and risks of anticoagulation therapy according to the degree of chronic kidney disease in patients with atrial fibrillation. BMC Cardiovasc Disord. 2023;23(1):1–9.
Montomoli M, Roca L, Rivera M, Fernandez-Prado R, Redondo B, Camacho R, et al. Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study. Healthc. 2022;10(12):1–10.
Yao X, Inselman JW, Ross JS, Izem R, Graham DJ, Martin DB, et al. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2020;13(10):E006515.
Park H, Yu HT, Kim TH, Park J, Park JK, Kang KW, et al. Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry. Yonsei Med J. 2023;64(1):18–24.
Vestergaard AEF, Jensen SK, Heide-Jørgensen U, Adelborg K, Birn H, Carrero JJ, et al. Oral anticoagulant treatment and risk of kidney disease—a nationwide, population-based cohort study. Clin Kidney J. 2024;17(1):1–9.
Bo D, Wang X, Wang Y. Survival benefits of oral anticoagulation therapy in acute kidney injury patients with atrial fibrillation: a retrospective study from the MIMIC-IV database. BMJ Open. 2023;13(1):1–8.
Calderon JM, Martinez F, Fernandez A, Sauri I, Diaz J, Uso R, et al. Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status. Sci Rep [Internet]. 2022;12(1):1–10. Available from: https://doi.org/10.1038/s41598-022-10164-5
Ha JT, Scaria A, Andrade J, Badve S V., Birks P, Bota SE, et al. Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada. Kidney Med [Internet]. 2023;5(7):100675. Available from: https://doi.org/10.1016/j.xkme.2023.100675
Rhee TM, Lee SR, Choi EK, Oh S, Lip GYH. Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022;9(June):1–11.
Dhaese SAM, De Vriese AS. Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation. Mayo Clin Proc. 2023;98(5):750–70.
Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774–82.
Kao TW, Chen ZW, Lin YH. Anticoagulation for Patients With Concomitant Atrial Fibrillation and End-Stage Renal Disease: A Systematic Review and Network Meta-Analysis. J Am Heart Assoc. 2024;13(8):e034176.
Hammett C, Badve S V., Kerr PG, Tran HA, Dundon BK, Lo S, et al. Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice. Hear Lung Circ [Internet]. 2022;31(12):1604–11. Available from: https://doi.org/10.1016/j.hlc.2022.09.003
Boriani G, Tartaglia E, Imberti JF. Oral anticoagulation for atrial fibrillation and high risk of bleeding in daily practice: What clinical considerations? Kardiol Pol. 2024;82(1):7–9.
Ren C, Zhao Y, Liu D. Effects of direct oral anticoagulants vs. vitamin K antagonists on acute kidney injury in patients with atrial fibrillation: A systematic review. Front Cardiovasc Med. 2023;10(2).
Chao TF, Chan NY, Chan YH, Cho MS, Krittayaphong R, Lee KN, et al. Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: An Asian Perspective. JACC Asia. 2023;3(5):707–23.
Kyriakoulis I, Adamou A, Stamatiou I, Chlorogiannis DD, Kardoutsos I, Koukousaki D, et al. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis. Eur J Intern Med [Internet]. 2024;119(July 2023):45–52. Available from: https://doi.org/10.1016/j.ejim.2023.08.020
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Muhammad Faiz Haidar Rafi, Riza Fadhila Muhammad (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
